Serum level of anti-mullerian hormone after exercise training in women with polycystic ovary syndrome: A randomized controlled trial

Iranian Journal of Obstetrics, Gynecology and Infertility

Volumn 16, Issue 64, 2013, Pages 10-18

  Saremi, Abbas ^a   Shavandi, Nader ^a   Karamali, Maryam ^a   Kazemi, Mozhgan ^a  

^a NONE

Author keywords

Anti mullerian hormone; Exercise; Infertility; Weight loss

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

AEROBIC EXERCISE; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; OBESITY; OVARY POLYCYSTIC DISEASE; OXYGEN CONSUMPTION; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84940333574     PISSN: 16802993     EISSN: 20082363     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Nazari T, Biat R. [Impact of metformin in girls with polycystic ovary syndrome] [Article in Persian]. Prolific Non Prolific J 2005;16:45-9.
2. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010 Feb;25(2):544-51.
3. Dunaif A. Drug insight: Insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal. Nat Clin Pract Endocrinol Metab 2008 May;4(5):272-83.
4. Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008 Feb;60(1):39-51.
5. Schuring AN, Schutie N, Sonntag B, Kiesel L. Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophsiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch 2008;48(1):9-15.
6. Speroff L, Fritz MA. Clinical gynecology endocrinology and infertility. 7th ed. Philadelphia:Lippincott Williams & Wilkins;2005:465.
7. Parco S, Novelli C, Vascotto F, Princi T. Serum anti-Müllerian hormone as a predictive marker of polycystic ovarian syndrome. Int J Gen Med 2011;4:759-63.
8. Pellatt L, Rice S, Dilaver N, Heshri A, Galea R, Brincat M, et al. Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril 2011 Nov;96(5):1246-51.
9. Nestler JE. Metformin in the treatment of infertility in PCOS: an alternative perspective. Fertil Steril 2008 Jul;90(1):14-6.
10. Neagu M, Cristescu C. Anti-Mu{double acute}llerian hormone--a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome. J Med Life 2012 Dec 15;5(4):462-4.
11. Ravn P, Haugen AG, Glintborg D. Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. Minerva Endocrinol 2013 Mar;38(1):59-76.
12. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19-25.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 Jul;28(7):412-19.
14. Heyward VH. Advanced fitness assessment exercise prescription. Champaign:Human Kinetics;1997.
15. Sam S, Duniaf A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003 Oct;14(8):365-70. Review.
16. Tabrizi FP, Alipoor B, Sadaghiani MM, Ostadrahimi A, Malek Mahdavi A. [Metabolic syndrome and its characteristics among reproductive-aged women with polycystic ovary syndrome: a cross-sectional study in northwest Iran. Int J Fertil Steril 2013 Winter;6(4):244-9.
17. Panidis D, Macut D, Tziomalos K, Papadakis E, Mikhailidis K, Kandaraki EA, et al. Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013 Apr;78(4):586-92.
18. Cobin RH. Cardiovascular and metabolic risks associated with PCOS. Intern Emerg Med 2013 Apr;8 Suppl 1:S61-4.
19. Amini M, Horri N, Farmani M, Haghighi S, Sattari G, Pornaghshband Z, et al. Prevalence of polycystic ovary syndrome in reproductive-aged women with type 2 diabetes. Gynecol Endocrinol 2008 Aug;24(8):423-7.
20. Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet 2013 Apr;113(4):520-45.
21. Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008 Sep;93(9):3373-80.
22. Orio F, Giallauria F, Palomba S, Manguso F, Orio M, Tafuri D, et al. Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women. Clin Endocrinol (Oxf). 2008;68(6):976-81.
23. Thomson RL, Buckley JD, Brinkworth GD. Exercise for the treatment and management of overweight women with polycystic ovary syndrome: a review of the literature. Obes Rev 2011 May;12(5):e202-10.
24. Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, et al. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002 Oct;87(10):4496-501.
25. Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab 2006 Aug;31(4):384-91.
26. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R, et al. Beneficial effects of a three-month structured exercise training program on the cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007 Apr;92(4):1379-84.
27. Palomba S, Giallauria F, Falbo A, Russo T, Oppedisano R, Tolino A, et al. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod 2007 Mar;23(3):642-50.
28. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschop M, Pasqali R. Plasma gherlin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 2002;87(12):5625-9.
29. Dokras A. Cardiovascular disease risk in women with PCOS. Steroids 2013 Aug:78(8):773-6.
30. Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010 May;139(5):825-33.
31. Eldar-Geva T, Margalioth EJ, Gai M, Ben-Chetrit A, Algur N, Zylber-Haran E, et al. Serum anti-Müllerian hormone levels during controlled ovarian hyperstimulation in women in polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005 Jul;20(7):1814-9.
32. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicle arrest. J Clin Endocrinol Metab 2003 Dec;88(12):5957-62.
33. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004 Jan;89(1):318-23.
34. La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004 Oct;82(4):970-2.
35. Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008 Apr;23(4):952-7.
36. Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, et al. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005 Jan;83(1):130-6.
37. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk Z, Paulson RJ. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril 2007 Apr;87(4):870-5.
38. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, et al. The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 2009 Aug;24(8):1976-81.
39. Moran LJ, Noakes M, Clifton PM, Norman RJ. The use of anti-mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007 Oct;92(10):3796-802.
40. Moran LJ, Harrison CL, Hutchison SK, Stepto NK, Strauss BJ, Teede HJ. Exercise decreases anti-müllerian hormone in anovulatory overweight women with polycystic ovary syndrome: a pilot study. Horm Metab Res 2011 Dec;43(13):977-9.
41. Carlsen SM, Vanky E, Fleming R. Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod 2009 Jul;24(7):1732-8.
42. Gougeon A, Lefevre B. Evolution of the diameters of the largest healthy and atretic follicles during the human menstrual cycle. J Reprod Fertil 1983 Nov;69(2):497-502.
43. Desforges-Bullet V, Gallo C, Lefebvre C, Pigny P, Dewailly D, Catteau-Jonard S. Increased anti-Mullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilisation. Fertil Steril 2010 Jun;94(1):198-204.